Loading
Coherus Oncology, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Stilwell McDavid, was filed 10 Jun 2021.
Coherus Oncology, Inc.: what insiders have been doing
This page follows insider dealings at Coherus Oncology, Inc. as filed with SEC (Form 4), a company from the Health Care sector. From 24 October 2025 to 24 October 2026, the disclosure feed for Coherus Oncology, Inc. logged 11 filings by 9 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Over the last twelve months, not one insider purchase of Coherus Oncology, Inc. stock was filed. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 11 filings, this issuer sits below that mark. Our records for Coherus Oncology, Inc. go back to 2016, with 1 purchase and 144 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at 168.0 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
326
Thresholds
n/a
Buy Volume
€40,771
1 ops. · all time
Sell Volume
€69M
144 ops. · all time
Who traded when
BuySaleMats Wahlstrom1 sale
Since the insiders bought
- -57.3%Entry US$14.50 · Close at T+365 US$6.19
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.96
Analyst consensus
4 analystsUS$4.00Target US$7.75(+708%)US$10.00
Income statement
RevenueUS$42.2M
Gross profitUS$28.4M67% margin
EBITDA-US$170.2M-404% margin
Net incomeUS$168M-259.4% margin
Valuation
PER (forward)-1.5x
P/Book2.4x
Beta0.99
Balance sheet & cash
Market capUS$148.1M
Total debtUS$40.3M
Free Cash Flow-US$138.5M
Debt / Equity89%
Profitability & ownership
ROE-178.4%
ROA-30.5%
% insiders19.1%
% institutions37.5%
Last declaration on 9 June 2026
Declarations326 total
30,000 shares0Common StockSEC:0001610717-26-000201:0
30,000 shares0Common StockSEC:0001610717-26-000200:0
30,000 shares0Common StockSEC:0001610717-26-000202:0
30,000 shares0Common StockSEC:0001610717-26-000203:0
30,000 shares0Common StockSEC:0001610717-26-000204:0
30,000 shares0Common StockSEC:0001610717-26-000205:0
30,000 shares0Common StockSEC:0001610717-26-000206:0
375,000 shares0Common StockSEC:0001610717-26-000027:0
112,500 shares0Common StockSEC:0001610717-26-000026:0
1,715 shares@ US$1.55100.0% of flowCommon StockSEC:0001610717-26-000017:0
11,839 shares@ US$1.55100.0% of flowCommon StockSEC:0001610717-26-000016:0
99,988 shares@ US$0.738934.0% of flowCommon StockSEC:0001610717-25-000145:0
11,810 shares@ US$1.394.6% of flowCommon StockSEC:0001610717-25-000013:0
1,711 shares@ US$1.398.1% of flowCommon StockSEC:0001610717-25-000015:0
4,858 shares@ US$1.3913.1% of flowCommon StockSEC:0001610717-25-000014:0
1,711 shares@ US$1.579.0% of flowCommon StockSEC:0001610717-25-000010:0
2,277 shares@ US$1.667.3% of flowCommon StockSEC:0001610717-25-000007:0
11,810 shares@ US$1.665.5% of flowCommon StockSEC:0001610717-25-000009:0
2,073 shares@ US$1.616.3% of flowCommon StockSEC:0001610717-24-000542:0
99,988 shares0Common StockSEC:0001610717-24-000060:1
99,988 shares0Common StockSEC:0001610717-24-000060:0
44,991 shares@ US$1.672.1% of flowCommon StockSEC:0001610717-24-000044:1
14,997 shares@ US$1.66712.0% of flowCommon StockSEC:0001610717-24-000044:0
11,218 shares@ US$2.447.2% of flowCommon StockSEC:0001610717-24-000039:0
1,707 shares@ US$2.4413.4% of flowCommon StockSEC:0001610717-24-000037:0
25 of 326 declarations
About Coherus Oncology, Inc.
Coherus Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of biosimilar therapies for cancer treatment. It is listed on NASDAQ under the ticker CHRS.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
